Aurelie Jaspers

Brussels, BRU, Belgium

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Late-onset neutropenia following ocrelizumab treatment in relapsing multiple sclerosis

Late-onset neutropenia following ocrelizumab treatment in relapsing multiple sclerosis

Journal: Revue medicale de Liege

Published: March 13, 2025

Real-world insights on the management of immune-mediated thrombotic thrombocytopenic purpura with caplacizumab.

Real-world insights on the management of immune-mediated thrombotic thrombocytopenic purpura with caplacizumab.

Journal: Blood vessels, thrombosis & hemostasis

Published: February 07, 2024

A rare case of massive myocardial infiltration by a disseminated extra-nodal NK/T-Cell lymphoma.

A rare case of massive myocardial infiltration by a disseminated extra-nodal NK/T-Cell lymphoma.

Journal: EJHaem

Published: January 14, 2022

Clofarabine added to intensive treatment in adult patients with newly diagnosed ALL: the HOVON-100 trial.

Clofarabine added to intensive treatment in adult patients with newly diagnosed ALL: the HOVON-100 trial.

Journal: Blood advances

Published: June 29, 2021

Erythroferrone and hepcidin as mediators between erythropoiesis and iron metabolism during allogeneic hematopoietic stem cell transplant.

Erythroferrone and hepcidin as mediators between erythropoiesis and iron metabolism during allogeneic hematopoietic stem cell transplant.

Journal: American journal of hematology

Published: March 18, 2021

Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS.

Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS.

Journal: Cancers

Published: December 17, 2020

Sickle cell disease and COVID-19: Atypical presentations and favorable outcomes.

Sickle cell disease and COVID-19: Atypical presentations and favorable outcomes.

Journal: EJHaem

Published: July 06, 2020

What is new in the management of multiple myeloma

What is new in the management of multiple myeloma

Journal: Revue medicale suisse

Published: August 24, 2018

Providing both autologous and allogeneic hematopoietic stem cell transplants (HSCT) may have a stronger impact on the outcome of autologous HSCT in adult patients than activity levels or implementation of JACIE at Belgian transplant centres.

Providing both autologous and allogeneic hematopoietic stem cell transplants (HSCT) may have a stronger impact on the outcome of autologous HSCT in adult patients than activity levels or implementation of JACIE at Belgian transplant centres.

Journal: Bone marrow transplantation

Published: August 03, 2018

Assessment and management of post-transplant iron overload: Guidelines of the Francophone Society of Marrow Transplantation and Cellular Therapy (SFGM-TC)

Assessment and management of post-transplant iron overload: Guidelines of the Francophone Society of Marrow Transplantation and Cellular Therapy (SFGM-TC)

Journal: Bulletin du cancer

Published: August 16, 2016

Erythropoietin therapy after allogeneic hematopoietic cell transplantation has no impact on long-term survival.

Erythropoietin therapy after allogeneic hematopoietic cell transplantation has no impact on long-term survival.

Journal: American journal of hematology

Published: June 17, 2015

Long-term safety follow-up of a randomized trial of darbepoetin alpha and intravenous iron following autologous hematopoietic cell transplantation.

Long-term safety follow-up of a randomized trial of darbepoetin alpha and intravenous iron following autologous hematopoietic cell transplantation.

Journal: American journal of hematology

Published: February 12, 2015

Showing 1-12 of 17

Last Updated: 09/26/2026